India, May 1 -- ARCHIMED, a leading investment firm focused exclusively on the healthcare industry, announced that it has entered into a definitive agreement under which ARCHIMED will acquire Esperion,(ESPR) a commercial-stage biopharmaceutical, in a transaction valued at up to $1.1 billion.
Under the terms of the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100 million in the aggregate tied to future net sales performance.The transaction is expected to close in the third quarter. The non-tradeable contingent value right (CVR) will entitle the holder to participate in two contingent milestone payments of up to $100 million in the a...